Hyperphosphataemia as an important complication of chronic renal insufficiency and chronic renal failure, part 2 - Treatment;Hyperfosfatemie jako závažná komplikace chronické renální insuficience a chronického selhání ledvin. II. Léčba

Vnitrni Lekarstvi

Volumn 51, Issue 3, 2005, Pages 337-344

  Smržová, Jana ^a  

^a UNIVERSITY HOSPITAL BRNO   (Czech Republic)

Author keywords

Haemodialysis; Hyperparathyroidism; Hyperphosphataemia; Phosphate binders; Renal bone disease; Renal insufficiency

Indexed keywords

ALFACALCIDOL; ALUMINUM MAGNESIUM HYDROXIDE; CALCITRIOL; CALCIUM ACETATE; CALCIUM CARBONATE; CALCIUM PHOSPHATE; CINACALCET; DOXERCALCIFEROL; GASTROGEL; LANTHANUM CARBONATE; PARATHYROID HORMONE; PARICALCITOL; PENTACAINE; PHOSPHATE BINDING AGENT; SEVELAMER; SUCRALFATE; VITAMIN D; VITAMIN D RECEPTOR;

BONE DISEASE; CALCIFICATION; CHRONIC KIDNEY FAILURE; DIALYSIS; DIET RESTRICTION; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; HYPERPHOSPHATEMIA; METABOLISM; MORTALITY; PARATHYROIDECTOMY; QUALITY OF LIFE; REVIEW; SECONDARY HYPERPARATHYROIDISM;

EID: 20344367067     PISSN: 0042773X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (43)

1. Andress DL, Norris KC, Coburn JW et al. Intravenous calcicriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med 1989; 321: 274-279.
2. Block GA, Hulbert-Shearon TE, Levin NW et al. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic haemodialysis patients. A national study. Am J Kidney Dis 1998; 31: 607-617.
3. Block GS, Martin KJ, de Francisco AL et al. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. NEJM 2004; 350: 1565-1567.
4. Braun J, Oldendorf M, Moshage W et al. Electron beam computed tomograpy in the evaluation of cardiac calcification in chronic dialysis patients. Am J Kidney Dis 1996; 27: 394-401.
5. Broulík P. Poruchy kalciofosfátového metabolismu. Praha: Grada 2003.
6. Coburn JW. Use of oral and parenteral calcitriol in the treatment of renal osteodystrophy. Kidney Int 1990; 38(Suppl): S54.
7. D'Haese PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int 2003; 85 (Suppl): S73-S78.
8. Date T, Shigematsu T, Kawashita Y et al. Colestimide can be used as a phosphate binder to treat uraemia in end-stage renal disease patients. Nephrol Dial Transplant 2003; 18(Suppl 3): iii90-93.
9. Delmez JA, Tindira CA, Windus DW et al. Calcium acetate as a phosphorus binder in hemodialysis patients. J Am Soc Nephrol 1992; 3: 96-102.
10. Don BR, Chin AI. A strategy for the treatment of calcific uremic arteriolopathy (calciphylaxis) employing a combination of therapies. Clin Nephrol 2003; 6: 463-470.
11. Dzúrik R, Spustová V. Nefrogénna metabolická acidóza. Vnitř Lék 2003; 49(5): 370-373.
12. Fine A, Zacharias J. Calciphylaxis is usually non-ulcerating: Risk factors, outcome and therapy. Kidney Int 2002; 61: 2210.
13. Finch JL, Brown AJ, Kubodera N et al. Differential effects of 1.25-(OH)2D3 and 22-oxacalcitriol on phosphate and calcium metabolism. Kidney Int 1993; 43: 561.
14. Finn WF, Joy MS, Webster I et al. A long term (2-year) assessment of the safety and efficacy of lanthanum carbonate, a non-calcium, non-aluminium phosphate binder, for the treatment of hyperphosphataemia. Poster at the 40th ERA-EDTA World Congress of Nephrology, Berlin, Germany, 8-12 June, 2003.
15. Chauveau P et al. Phosphate removal rate: a comparative study of five high-flux dialysers. Nephrol Dial Transplant 1992; 2(Suppl): 114-115.
16. Chertow GM, Dillon M, Burke SK et al A randomized trial of sevelamer hydrochloride (RenaGel) with and without supplemental calcium. Strategies for the control of hyperphosphatemia and hyperparathyroidism in hemodialysis patients. Clin Nephrol 1999; 51: 18-26.
17. Lefebvre A, de Vernejoul MC, Gueris J et al. Optimal correction of acidosis changes progression of dialysis osteodystrophy. Kidney Int 1989; 36: 1112-1118.
18. Locatelli F, Cannata-Andia JB, Drucke T et al. Management of disturbancies of calcium and phosphate metabolism in chronic renal insufficiency, with emphasis on the control of hyperphosphataemia. Nephrol Dial Transplant 2002; 17: 723-731.
19. Locatelli F, Del Vecchio I, Pozzoni P. The importance of early detection of chronic kidney disease. Nephrol Dial Transplant 2002; 17(Suppl 1): 2-7.
20. Loghman-Adham M. Safety of new phosphate binders for chronic renal failure. Drug Saf 2003; 26: 1093-1115.
21. Martin KJ, Gonzalez E, Gellens M et al. 19-Nor-1-alpha-25- dihydroxyvitamin D2 (Paricalcitol) safely and effectively reduces the levels of intact parathyroid hormone in patients on hemodialysis. J Am Soc Nephrol 1998; 9: 1427-1432.
22. Molitoris BA, Froment DH, Mackenzie TA et al. Citrate: A major factor in the toxicity of orally administered aluminum compounds. Kidney Int 1989; 36: 949-953.
23. National Kidney Foundation. K/DO-QI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42 (Suppl 3): S1-201.
24. Raggi P, Boulay A, Chasan-Taber S et al. Cardiac calcification in adult hemodialysis patients. A link between end/stage renal disease and cardiovascular disease? J Am Coll Cardiol 2002; 39(4): 695-701.
25. Salusky IB, Foley J, Nelson P et al. Aluminum accumulation during treatment with aluminum hydroxide and dialysis in children and young adults with chronic renal disease. N Engl J Med 1991; 324: 527-531.
26. Sellarez LV, Ramirez TA. Management of hyperphosphataemia in dialysis patients: role of phosphate binders in the elderly. Drugs Aging 2004; 21: 153-165.
27. Schiller LR, Santa Ana CA, Sheikh MS et al. Effect of the time of administration of calcium acetate on phosphorus binding. N Engl J Med 1989; 320: 1110-1113.
28. Schück O, Tesař V, Teplan V et al. Konzervativní léčení chronického selhání ledvin. In: Schück O. Klinická nefrologie. Praha: Medprint 1995:179-198.
29. Slatopolsky E, Burke SK, Dillon MA. RenaGel, a nonabsorbed calcium- and aluminum-free phosphate binder, lowers serum phosphorus and parathyroid hormone. The RenaGel study group. Kidney Int 1999; 55: 299-307.
30. Slatopolsky E, Finch J, Denda M et al. Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro. J Clin Invest 1996; 97: 2534-2540.
31. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161.
32. Slacopolsky E, Berkoben M, Kelber J et al. Effects of calcitriol and non-calcemic vitamin D analogs on secondary hyperparathyroidism. Kidney Int 1992; 38(Suppl): S43-49.
33. Slatopolsky E, Weerts C, Thielan J et al. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1.25- dihydroxycholecalciferol in uremic patients. J Clin Invest 1984; 74: 2136-2143.
34. Slatopolsky E. The interaction of parathyroid hormone and aluminum on renal osteodystrophy. Kidney Int 1987; 31: 842-854.
35. Sotornik I et al. Kostní choroba při nezvratném selhání ledvin. Praha: Scientia Medica 1994.
36. Sotorník I, Bubeníček P, Adamec M et al. Poruchy funkce příštítných tělísek u nemocných v pravidelném dialyzačním léčení a po transplantaci ledviny. Čas Lěk Čes 2003; 4: 229-234.
37. Sotorník I, Bubeníček P. Kostní choroba u nemocných s chronickým selháním ledvin II. část: Diagnostika a léčeni kostní choroby. Osteol Bul 2000; 4: 114-122.
38. Sotorník I, Petrásek R, Schück O et al. Nárazové dávky kalcitriolu při léč ení sekundární hyperparatyreózy u hemodialyzovaných nemocných. Vnitř Lék 1997; 43(9): 584-591.
39. Stracke S, Jehle PM, Sturm D et al. Clinical course after total parathyroidectomy without autotransplantation in patients with end-stage renal failure. Am J Kidney Dis 1999; 33: 304-311.
40. Sulková S et al. Renální osteopatie. In: Sulková S. Hemodialýza. Praha: Maxdorf 2000.
41. Sulková S, Fořtová M, Válek M et al. Renální kostní choroba. Vnitř Lék 2003; 49(5): 403-408.
42. Sulková S. Epidemiologie funkčniho postižení ledvin. Vnitř Lék 2003; 49(5): 358-361.
43. Tan AU, Levine BS, Mazess RB et al. Effective suppression of parathyroid hormone by 1-alpha-hydroxy-vitamin D2 in hemodialysis patients with moderate to severe secondary hyperparathyroidism. Kidney Int 1997; 51: 317-323.